Source:European Journal of Cancer, Volume 87
Author(s): Peter C. Albertsen
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jBLLRF
via IFTTT
Παρασκευή 1 Δεκεμβρίου 2017
Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists
Source:European Journal of Cancer, Volume 87
Author(s): Peter C. Albertsen
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jBLLRF
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Early Antarctic ice age dynamics Antarctica. Image courtesy of Wikimedia Commons/Dave Pape. The extent of Antarctic ice sheets oscillated wi...
-
A host of new therapies are now available for treating patients with chronic lymphocytic leukemia (CLL) in both the upfront and relapsed or ...
-
Related Articles Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch. 2017...
-
We thank Liu et al. (1) for their comments on our paper (2). The first point of Liu et al. (1) is that the Lake Dali Early Holocene highstan...
-
Abstract Background The role of thymectomy in the treatment of juvenile myasthenia gravis (JMG) is poorly defined. The objective of this...
-
In PNAS, Krementsov et al. (1) report that if you are a male mouse and catch the flu, the severity of your illness may depend on the type of...
-
Biomarker testing is recommended for all patients diagnosed with non–small cell lung cancer. At a minimum, testing should include the mutati...
-
American Thyroid Resarch Grant to Nikita Pozdeyev, MD, PhD, University of Colorado Newswise (press release) The 2016 Research Grant h...
-
In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer, among adjuvant radiotherapy options for whole-brea...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου